Sign In

Scott Gottlieb

Partner, New Enterprise Associates

Professional Background

Scott Gottlieb is a distinguished public health expert, physician, and business leader who has made significant contributions in the fields of medicine, biotechnology, and public policy. He served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019, a tenure marked by pivotal advancements in drug approval processes and public health initiatives. Currently, Scott holds a position as a Resident Fellow at the American Enterprise Institute (AEI) and is a Partner at New Enterprise Associates (NEA), a prominent venture capital firm. He is also a contributor to CNBC, where he shares his insights on health policy and the health care industry.

Throughout his expansive career, Scott has been an invaluable asset to various organizations, holding crucial positions on boards such as Pfizer, Illumina, Aetion, and Tempus Labs, which are leaders in pharmaceuticals and healthcare technology. His diverse experiences have provided him with a unique perspective on the intersection of medicine, regulatory affairs, and business strategy.

Education and Achievements

Scott Gottlieb's academic journey laid the foundation for his illustrious career. He earned his Doctor of Medicine (MD) degree from the prestigious Mount Sinai School of Medicine at New York University, where he also completed his residency in internal medicine. Prior to his medical training, Scott received a Bachelor of Arts in Economics from Wesleyan University, where he developed a strong analytical and quantitative skill set that would later prove beneficial in his medical and business endeavors.

Scott's extensive contributions to medicine and regulatory science have not gone unnoticed. He was elected as a member of the National Academy of Medicine, reflecting his significant accomplishments and thought leadership in the field. His commitment to improving public health is further evidenced by his work on various health policy committees, including his role as a member of the Federal Health IT Policy Committee at the U.S. Department of Health and Human Services (HHS). His expertise in both clinical practice and health policy makes him a sought-after advisor and board member at various health and technology companies.

Contributions to Health Policy and Leadership

During his time as FDA Commissioner, Scott Gottlieb championed many initiatives that prioritized public health, including the accelerated approval of generic drugs, which aimed to reduce prescription drug costs for patients and foster competition in the market. He played a crucial role in the FDA's efforts to combat the opioid epidemic through comprehensive strategies that included improved labeling on opioid medications and increased access to addiction treatments. His leadership was instrumental in addressing key health concerns, ensuring that the FDA remained at the forefront of public health and safety.

In addition to his regulatory work, Scott has made significant contributions as an author and thought leader, frequently sharing his insights on current health policy issues and developments in the pharmaceutical industry. His ability to bridge the gap between complex medical science and practical policy implementation has established him as a key voice in health care discussions across various platforms.

Board Membership and Advisory Roles

Scott Gottlieb has held numerous prestigious positions across a range of organizations, significantly influencing the fields of health care and biotechnology. In addition to his ongoing role as a Partner at New Enterprise Associates, he has formerly held independent positions on the boards of directors for notable pharmaceutical and health care companies such as Tolero Pharmaceuticals, Daiichi Sankyo, and Bravo Health. His diverse experience on these boards not only underscores his commitment to advancing innovative health solutions but also highlights his strategic acumen in navigating the complexities of the healthcare marketplace.

His extensive involvement also includes serving as a member of the Policy Board at The Leukemia & Lymphoma Society and the Society of Hospital Medicine, where he has helped shape strategies that promote health equity and improve patient care standards. As a Clinical Assistant Professor at NYU Langone Health, Scott has shared his extensive knowledge and guided the next generation of healthcare leaders, fostering an environment of learning and innovation.

Transition to Venture Capital

After his impactful tenure at the FDA, Scott Gottlieb transitioned into the realm of venture capital, applying his extensive experience in medicine and policy to identify and support emerging healthcare technologies. As a Partner at NEA, he leverages his comprehensive knowledge of the healthcare landscape to guide investments in innovative companies that are poised to make significant advancements in patient care and health outcomes. By combining clinical insight with investment strategies, Scott plays a vital role in shaping the future of health care.

Scott Gottlieb’s career is characterized by a profound commitment to improving public health and advancing medical innovation. His steadfast dedication to the health care field and his continuous pursuit of excellence have established him as a leading authority in health policy and regulatory affairs. Through his leadership roles, Scott has consistently sought to address the pressing health challenges of our time, ensuring that the needs of patients remain at the forefront of all initiatives.

As he continues to contribute to public health discussions and drive innovation in the healthcare and biotechnology sectors, Scott Gottlieb is undoubtedly a figure who will shape the future of these industries for years to come.

Related Questions

How did Scott Gottlieb's education at Mount Sinai School of Medicine influence his career in health policy?
What innovative initiatives did Scott Gottlieb implement during his tenure as FDA Commissioner?
In what ways is Scott Gottlieb contributing to the future of biotechnology as a Partner at NEA?
How has Scott Gottlieb's background in economics impacted his approach to health care policy?
What are some notable projects that Scott Gottlieb has supported on the boards of leading health organizations like Pfizer and Illumina?
Scott Gottlieb
Add to my network

Location

Washington, District Of Columbia